Adoptive T-Cell Therapy Congress, taking place March 15-16, 2016.

Join the industries scientific and business leaders as we discuss adoptive T-cell therapies for cancer by looking at ways forward in improving efficiency and efficacy, case studies on liquid and solid tumours, scalability, manufacture and progress within industry regulation. The congress will focus on academic collaboration, networking and business partnering within the fields of CAR-T, TCR’s and TIL’s with sessions including: advancements in T-cell engineering; efficacy in different cancer models and results from human and clinical studies.

Attending the congress brings you together with thought leaders from biotech, big pharma and academia and the wider service community and gives you access to strategies that are critical to furthering the development of viable t-cell therapies.

Hosted by Kisaco Research, this B2B Adoptive T-Cell Therapy Congress conference will cover:

•             Advancements in T-cell engineering

•             Efficacy in different cancer models

•             Results from human and clinical studies

•             Commercialisation of Viable T-cell therapies

•             Scaling and manufacture of T-cells

Download the program online at www.tcellcongress.comor contact events@kisacoresearch.comfor a copy of the agenda today. Save 15% off industry rates when you book online with DL15.